Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTCXNASDAQ:NRXSNASDAQ:NTRBNASDAQ:VANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$2.73-7.1%$1.14$0.17▼$2.60$57.07M0.513.90 million shs79,873 shsNRXSNeurAxis$2.66+1.9%$2.29$1.33▼$6.20$19.20M3.34411,537 shs75,852 shsNTRBNutriband$7.79+1.2%$5.77$3.72▼$11.78$86.89M1.1180,667 shs60,552 shsVANIVivani Medical$1.15$1.07$0.91▼$2.09$68.13M2.93161,657 shs44,568 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell0.00%-17.27%+1,661.29%+1,258.21%+6.64%NRXSNeurAxis0.00%-4.40%+30.50%+21.40%-12.71%NTRBNutriband0.00%+23.79%+34.62%+23.20%+48.08%VANIVivani Medical0.00%-7.28%+11.11%+10.58%-28.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/ANRXSNeurAxis1.9144 of 5 stars0.05.00.00.03.33.30.0NTRBNutriband2.2662 of 5 stars3.52.00.00.02.31.70.6VANIVivani Medical3.2037 of 5 stars3.55.00.00.02.23.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTCXCarmell 0.00N/AN/AN/ANRXSNeurAxis 0.00N/AN/AN/ANTRBNutriband 3.00Buy$13.0066.88% UpsideVANIVivani Medical 3.00Buy$4.00247.83% UpsideCurrent Analyst Ratings BreakdownLatest NRXS, VANI, CTCX, and NTRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/16/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/4/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/26/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/13/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 6/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTCXCarmell$32.84K1,737.89N/AN/A$1.07 per share2.55NRXSNeurAxis$2.93M6.54N/AN/A($0.27) per share-9.85NTRBNutriband$2.40M36.23N/AN/A$0.73 per share10.67VANIVivani MedicalN/AN/AN/AN/A$0.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/ANRXSNeurAxis-$14.63M-$1.19N/A∞N/A-492.76%N/A-641.25%N/ANTRBNutriband-$5.49M-$0.90N/AN/AN/A-338.51%-54.49%-48.52%N/AVANIVivani Medical-$25.65M-$0.43N/AN/AN/AN/A-102.42%-49.21%8/12/2025 (Estimated)Latest NRXS, VANI, CTCX, and NTRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q1 2026NTRBNutriband-$0.13-$0.12+$0.01-$0.12$0.71 million$0.67 million5/13/2025Q1 2025VANIVivani Medical-$0.10-$0.11-$0.01-$0.11N/AN/A4/28/2025Q4 2025NTRBNutriband-$0.12-$0.18-$0.06-$0.51$0.71 million$0.64 million3/31/2025Q4 2024VANIVivani Medical-$0.10-$0.11-$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTCXCarmellN/AN/AN/AN/AN/ANRXSNeurAxisN/AN/AN/AN/AN/ANTRBNutribandN/AN/AN/AN/AN/AVANIVivani MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTCXCarmellN/A0.310.29NRXSNeurAxisN/A0.240.23NTRBNutriband0.014.964.83VANIVivani MedicalN/A3.413.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTCXCarmell24.22%NRXSNeurAxis11.77%NTRBNutriband19.70%VANIVivani Medical6.78%Insider OwnershipCompanyInsider OwnershipCTCXCarmell29.00%NRXSNeurAxis26.40%NTRBNutriband54.09%VANIVivani Medical46.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableNRXSNeurAxis197.22 million6.09 millionNot OptionableNTRBNutriband1011.15 million5.10 millionNot OptionableVANIVivani Medical2059.24 million32.99 millionOptionableNRXS, VANI, CTCX, and NTRB HeadlinesRecent News About These CompaniesVivani Stock Gains After Announcing Spin-Off Plans for Cortigent UnitJune 2, 2025 | zacks.comCompanies To Watch: Vivani MedicalMay 30, 2025 | lifescienceleader.comVivani files with SEC to spin off neurostim business, focus on drug delivery implantsMay 29, 2025 | massdevice.comVivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani ShareholdersMay 29, 2025 | finance.yahoo.comHC Wainwright Estimates Vivani Medical Q1 EarningsMay 24, 2025 | marketbeat.comVivani Medical (NASDAQ:VANI) Receives Buy Rating from HC WainwrightMay 21, 2025 | marketbeat.comVivani Medical Reports Q1 2025 Results and Strategic UpdatesMay 20, 2025 | tipranks.comVivani Medical, Inc.: Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial ResultsMay 15, 2025 | finanznachrichten.deVivani Medical, Inc. Reports Successful Initial Data from LIBERATE-1™ Study and Secures $3M in Equity FinancingMay 13, 2025 | quiverquant.comVivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comVivani Medical CEO to Present on Innovative Drug Delivery Solutions at AAPS Virtual WorkshopMay 9, 2025 | nasdaq.comVivani Medical to Present at the American Association of Pharmaceutical Scientists' “Beyond GLP1s: Where the Science will Take Business Next” Virtual WorkshopMay 7, 2025 | globenewswire.comVivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & CompanyApril 16, 2025 | finance.yahoo.comVivani Medical, Okava expand collaboration to develop OKV-119 for dogsApril 16, 2025 | markets.businessinsider.comVivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and LongevityApril 15, 2025 | globenewswire.comGregg Williams Purchases 18,529 Shares of Vivani Medical, Inc. (NASDAQ:VANI) StockApril 12, 2025 | insidertrades.comVivani Medical, Inc. (NASDAQ:VANI) Director Purchases $33,660.00 in StockApril 9, 2025 | insidertrades.comWeight loss implants to increase compliance and cut admin burden for patientsApril 3, 2025 | finance.yahoo.comVivani Medical Reports 2024 Financial Results and Business ProgressApril 1, 2025 | tipranks.comVivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 31, 2025 | globenewswire.comVivani Medical prices 7.4M shares at $1.12 in private placement financingMarch 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRXS, VANI, CTCX, and NTRB Company DescriptionsCarmell NASDAQ:CTCX$2.73 -0.21 (-7.14%) As of 06/6/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.NeurAxis NASDAQ:NRXS$2.66 +0.05 (+1.92%) Closing price 04:00 PM EasternExtended Trading$2.67 +0.01 (+0.34%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.Nutriband NASDAQ:NTRB$7.79 +0.09 (+1.17%) Closing price 04:00 PM EasternExtended Trading$7.66 -0.13 (-1.60%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.Vivani Medical NASDAQ:VANI$1.15 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.15 0.00 (-0.35%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Tightly-Held Growth Stocks Set Up for Short Squeezes Palantir Stock Holds Support, Despite Political Backlash Science Applications International Is a Wicked Hot Buy in June Why Unity Software May Be the AI Breakout No One Saw Coming Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead? Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
